Athelas Acquisition, Valuation, Funding & Investors

Athelas was acquired by Commure for $6B in October 2023, a 60.0x multiple on $100M of revenue.

Athelas acquisition price

$6B

Acquired by Commure · Oct 2023

Athelas revenue at acquisition

$100M

Last twelve months · Oct 2023

Athelas revenue multiple at acquisition

60.0x

EV/Revenue · Oct 2023

Cumulative funding Athelas raised

$150M

across 4 funding rounds

Athelas Overview

About Athelas

Athelas is a remote patient monitoring company deploying FDA-cleared devices for chronic conditions. San Francisco-headquartered, it tracks blood pressure, weight, glucose, and medication adherence via sensors in homes. Founded in 2015, the platform serves Medicare Advantage plans and integrates with electronic health records for over 10,000 patients.


Founded

2016

HQ

United StatesSan Francisco, CA

Status

Acquired

Customer focus

B2B

Revenue model

Subscription, Usage-based

Revenue

$100M (Oct 2023)

Valuation

$1.5B (Jan 2022)

Athelas Acquisition

Athelas was acquired by Commure for $6B on 4 October 2023.

The acquisition price implies a 60.0x revenue multiple on $100M of revenue.

Before the acquisition Athelas had raised $150M across 4 funding rounds.

Athelas acquisition details
AcquirerDateTypePriceEV/Revenue
4 Oct 2023Strategic M&A$6B60.0x

Athelas Valuation

Athelas is currently valued at $1.5B, based on its Series C in January 2022.

The $59M round was led by Tribe Capital, with participation from Greenoaks, Y Combinator, Initialized Capital, Human Capital, Fifty Years and 1 other investor.

Athelas' valuation has moved from $1.5B at its Series B in August 2021 to $1.5B in January 2022, across 2 priced rounds.

Athelas valuation by funding round

Athelas valuation by funding round
DateStageValuation
Jan 2022Series C$1.5B
Aug 2021Series B$1.5B

Athelas Funding History

Athelas has raised a total of $150M across 4 funding rounds.

Athelas' first fundraising round was a $4M seed round in August 2017. The most recent completed round was a $59M Series C in January 2022.

Athelas funding rounds

Athelas funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jan 2022Series CTribe Capital (lead); Greenoaks; Y Combinator; Initialized Capital; Human Capital; Fifty Years; Sequoia Capital$59M$1.5BAthelas, a Mountain View, California-based HealthTech company founded in 2016, develops remote patient monitoring devices and automation solutions, including the Athelas One smartphone-attached tool for measuring white-blood-cell counts and other blood testing, medication adherence devices for chronic condition management, partnering with hospitals and health systems. The company originated from a 2014 hackathon project by CEO Tanay Tandon and cofounder Deepika Bodapati. Athelas graduated from Y Combinator in 2016 and had grown to serve over 40,000 patients with chronic conditions by January 2022. On January 31, 2022, Athelas raised $59.4 million in a Series B or Venture round led by Tribe Capital, part of a larger $132 million total across two closely announced rounds (the other led by General Catalyst, approximately $73 million closing in April 2021). Participating investors included Sequoia Capital, Greenoaks, Human Capital, Initialized Capital, and Y Combinator, matching the specified investors. This funding brought the post-money valuation to $1.5 billion, achieving unicorn status, with proceeds aimed at accelerating product innovation, expanding healthcare partnerships, and scaling remote patient monitoring infrastructure. Prior rounds included a $3.7 million Seed VC in 2017 led by Sequoia Capital and Initialized Capital, and earlier seed funding. By January 2022, Athelas had raised approximately $136 million total across multiple rounds, employing over 300 people. The company later merged with Commure on October 4, 2023, forming an entity valued at $6 billion, and continued developments in revenue cycle management and AI clinical workflows.
Aug 2021Series BGeneral Catalyst (lead); Human Capital; Tribe Capital; Adam Guild$72M$1.5BAthelas is a healthtech company founded in 2016 and headquartered in Mountain View, CA, specializing in remote patient monitoring, automation, AI-powered healthcare solutions including revenue cycle management, ambient AI clinical workflows, and practice management OS. The company has raised over $136 million across multiple rounds prior to later developments, with key investors including General Catalyst, Tribe Capital, Sequoia Capital, and Y Combinator. A Series B round on April 16, 2021, raised $72 million, matching one of the specified investors General Catalyst. The subsequent Series C round in January 2022 raised $132 million led by General Catalyst with participation from Tribe Capital, achieving a post-money valuation of $1.5 billion, which sources associate with the company's growth during the pandemic boom in remote monitoring technologies. Funds were used to accelerate product development, expand healthcare partnerships, scale remote patient monitoring infrastructure, grow the team to over 300 employees, and pursue global operations. Athelas continued expansion with a $200 million growth round in 2025 from General Catalyst's Customer Value Fund to enhance AI innovations and customer success amid surging demand. In 2023, Athelas merged with Commure in a $6 billion deal, further integrating its offerings into broader healthcare software platforms.
Feb 2019Series AGeorges Harik (lead); Fifty Years; Sequoia Capital$15M--
Aug 2017SeedSequoia Capital (lead)$4M-Athelas raised $3.7 million in a seed round in August 2017 led by Sequoia Capital, with participation from Initialized Capital and Liquid 2 Ventures. The funding supported commercialization of its WBC blood testing device and expansion of R&D efforts. Athelas, founded in 2016 by Tanay Tandon, develops healthcare technology including remote patient monitoring and data-driven insights. The company later scaled with additional rounds, including a $132 million Series A in January 2022 led by General Catalyst and Tribe Capital, achieving a $1.5 billion valuation. Athelas focused on product innovation, healthcare partnerships, and remote patient monitoring infrastructure. In October 2023, Athelas merged with Commure, integrating its remote patient monitoring and revenue cycle management tools.

Who has invested in Athelas?

10 investors have backed Athelas across its funding rounds, including Sequoia Capital, Tribe Capital, Human Capital, Fifty Years, Y Combinator and General Catalyst.

Lead investors include Tribe Capital, General Catalyst, Georges Harik and Sequoia Capital.


Athelas Investors

Investors in Athelas by funding rounds participated
InvestorHQRoundsRoleFirst check
Sequoia CapitalUnited StatesSan Francisco, CA3LeadAug 2017
Human CapitalUnited StatesSan Francisco, CA2ParticipantAug 2021
Fifty YearsUnited StatesSan Francisco, CA2ParticipantFeb 2019
Tribe CapitalUnited StatesSan Francisco, CA2LeadAug 2021
General CatalystUnited StatesSan Francisco, CA1LeadAug 2021
GreenoaksUnited StatesSan Francisco, CA1ParticipantJan 2022
Y CombinatorUnited StatesSan Francisco, CA1ParticipantJan 2022
Georges HarikUnited StatesSan Francisco, CA1LeadFeb 2019

This data is available for Pro users. Sign up to see all 10 Athelas investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Athelas Competitors

Athelas competitors include listed companies like Solventum, Abbott India, Caris Life Sciences and Glaukos, and private ones like WeDoctor and Noom.

Public and private companies comparable to Athelas
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
WeDoctorChinaHangzhouPrivate$139M-$7B50.4x
NoomUnited StatesNew York City, NYPrivate$400M-$3.7B9.3x
SolventumUnited StatesUnited StatesPublicly listed$8.3B$2.5B$15B2.4x
Abbott IndiaIndiaIndiaPublicly listed$722M$199M$5.7B7.4x
Caris Life SciencesUnited StatesUnited StatesPublicly listed$812M($5M)$8.7B8.7x
GlaukosUnited StatesUnited StatesPublicly listed$507M($157M)$9.5B14.6x

Athelas Public Comps

Athelas is no longer listed, but its public comps include Bausch + Lomb, Horiba, Minimed Group, Sectra, Snibe, Abbott India, Cochlear, Asahi Intecc, Convatec Group and Ypsomed.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Bausch + Lomb$5.1B$513M2.1x2.0x21.3x11.0x
Horiba$2.1B$408M2.5x2.2x12.9x9.9x
Minimed Group$3.1B($33M)1.9x1.9x(181.8x)12.1x
Sectra$362M$84M15.5x14.2x66.8x59.1x
Snibe$682M$301M8.0x7.4x18.0x16.5x
Abbott India$722M$199M7.7x7.4x27.7x26.5x
Cochlear$1.7B$229M3.8x3.8x27.8x17.3x
Asahi Intecc$772M$186M6.8x5.6x28.2x15.0x

This data is available for Pro users. Sign up to see all Athelas competitors and their valuation data.

Start Free Trial

Common questions about Athelas

When was Athelas founded?Athelas was founded in 2016.
Where is Athelas headquartered?Athelas is headquartered in San Francisco, CA, United States.
Is Athelas publicly listed?No, Athelas was acquired by Commure in October 2023.
Who acquired Athelas?Athelas was acquired by Commure in October 2023.
How much was Athelas acquired for?Athelas was acquired for $6B in October 2023, a 60.0x revenue multiple.
What is Athelas' valuation?Athelas was last valued at $1.5B in its Series C in January 2022.
How much funding has Athelas raised?Athelas has raised $150M across 4 funding rounds.
What was Athelas' last funding round?Athelas' last funding round was a $59M Series C in January 2022, led by Tribe Capital.
Who are Athelas' investors?Athelas' investors include Sequoia Capital, Human Capital, Fifty Years, Tribe Capital, General Catalyst, Greenoaks, Y Combinator, Georges Harik, Initialized Capital and Adam Guild.
Which companies are comparable to Athelas?Companies comparable to Athelas include WeDoctor, Noom, Solventum, Abbott India, Caris Life Sciences and Glaukos.

See companies similar to Athelas

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial